Aruba vs Bonaire, Sint Eustatius and Saba: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Aruba
0.2%
in 2024
Bonaire, Sint Eustatius and Saba
0.2%
in 2024
Aruba rank
98th
Bonaire, Sint Eustatius and Saba rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Aruba
- Bonaire, Sint Eustatius and Saba
How they compare
Aruba currently reports 0.2% against 0.2% in Bonaire, Sint Eustatius and Saba, a difference of 0.0%.
Across all 10 years both countries report, Bonaire, Sint Eustatius and Saba has been ahead every year.
Aruba ranks 98th and Bonaire, Sint Eustatius and Saba ranks 98th of 246 countries.
Head to head by decade
| Decade | Aruba | Bonaire, Sint Eustatius and Saba | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | — |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Aruba or Bonaire, Sint Eustatius and Saba?
- Aruba, at 0.2% against 0.2% in Bonaire, Sint Eustatius and Saba as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Aruba and Bonaire, Sint Eustatius and Saba?
- 0.0%, with Aruba ahead.
- How many years of comparable data are there for Aruba and Bonaire, Sint Eustatius and Saba?
- 10 years are reported by both, from 2015 to 2024.
- How do Aruba and Bonaire, Sint Eustatius and Saba rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Aruba ranks 98th and Bonaire, Sint Eustatius and Saba ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.